Loading stock data…
Agios Pharmaceuticals, Inc. (AGIO)
$37.78-0.12 (-0.30%)
Market OpenUpdated 3:07 PM EDT
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Agios Pharmaceuticals, Inc. in the Healthcare sector is trading at $37.70 with a market capitalization of $1.6B. Wall Street consensus targets $40.75 (8 analysts), implying a +8.1% move over the next 12 months. The stock is currently 18% below its 52-week high of $46.00, remaining 18.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +8.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $20.75M↑ | $19.97M↑ | $12.88M↑ | $12.46M↑ | $8.73M |
| Gross Profit | $19.43M↑ | $18.09M↑ | $11.20M↑ | $10.75M↑ | $7.64M |
| Operating Income | -$110.03M↑ | -$121.58M↓ | -$116.87M↑ | -$127.06M↓ | -$106.63M |
| Net Income | -$99.11M↑ | -$108.04M↓ | -$103.43M↑ | -$112.02M↓ | -$89.29M |
Peer Comparison
JNJUNHPFE
Fundamentals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.65B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.58
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.38%
Volume
Today's trading volume
357,448
Recent News
AGIO Stock Surges 35% in Six Months: What's Driving It?
Agios' shares rose 35% in six months as Aqvesme gains traction, mitapivat expands globally and new ITP rights add to its rare blood disease push.
Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss
Agios Pharmaceuticals (NASDAQ:AGIO) used an investor webcast tied to the 2026 European Hematology Association Congress in Stockholm to highlight new clinical data for mitapivat across thalassemia and sickle cell disease, while outlining a broader rare disease strategy that now includes multiple hema
Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
How The Tebapivat Setback Is Reframing The Story For Agios Pharmaceuticals (AGIO)
The modelled fair value for Agios Pharmaceuticals edges slightly lower from US$41.13 to US$40.88 per share, aligning with recent tweaks to analysts’ price targets in the wake of the tebapivat update. This modest shift mirrors a split Street view, where some firms are trimming targets toward US$40 while others, such as Citi at US$46, are leaning more on mitapivat and upcoming regulatory catalysts. Read on to see how to track these moving targets and make sense of the evolving narrative around...
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate
Agios gains global rights to cevidoplenib for ITP, adding a late-stage rare hematology asset with up to $1B U.S. peak sales potential.